Abstract Library
Members may log into MY ENETS to visit the abstract library from previous ENETS conferences.
Participants of the ENETS Conference in 2024 can now access the abstract booklet, e-posters and videos, slide decks of talks, the poster carousel, and more via My ENETS.
ENETS Abstract Search
Introduction: CALM-NET (EudraCT 2013-002194-22; NCT02075606) evaluated pre-treatment circulating tumour cell levels in patients with NETs as a predictor of response to lanreotide autogel (LAN).
Conference: 17th Annual ENETSConcerence (2020)
Presenting Author:
Authors: Shah T, Caplin M, Khan M, Houchard A, Furnace M,
Keywords: neuroendocrine tumours, lanreotide, biomarkers,
Introduction: A new lanreotide autogel/depot (LAN) syringe was developed based on feedback from a human factors study to improve user experience.
Conference: 17th Annual ENETSConcerence (2020)
Presenting Author:
Authors: Truong Thanh X, Adelman D, Feuilly M, Houchard A, Cella D,
Keywords: Somatuline lanreotide, syringe, neuroendocrine tumors, medical treatment,
Introduction: PanNETs are the second most common type of tumour of the pancreas. Most patients have metastatic disease at diagnosis with median survival ranges from 2 to 5 years. Somatostatin analogs (SSAs) control symptoms and reduce tumour growth in panNET. In the panNET subgroup of the CLARINET study, lanreotide autogel 120 mg reduced the relative risk of progression or death by more than 40% compared with placebo at week 96.
Conference: 17th Annual ENETSConcerence (2020)
Presenting Author:
Authors: Teulé A, Alonso T, González E, De La Cruz G, Houchard A,
Keywords: NET, lanreotide, pancreas, study,
Introduction: Information provided to patients about burden and treatment of neuroendocrine tumors (NETs) may ease treatment adherence, outpatient monitoring, and improve quality of life (QoL), but can also cause anxiety. Data on how to individually adapt materials are insufficient and mainly derived from clinical trials.
Conference: 15th Annual ENETSConcerence (2018)
Presenting Author:
Keywords: patients perception of information, QoL, lanreotide,
Introduction: Telotristat ethyl (TE) is an oral tryptophan hydroxylase inhibitor in development for treating CS symptoms. During the double-blind treatment [DBT] period of the phase 3, 12-week, placebo-controlled TELESTAR study, TE was well tolerated and significantly reduced bowel-movement frequency and u5-HIAA levels compared with placebo (PBO) in NET patients with CS treated with a SSA.
Conference: 14th Annual ENETSConcerence (2017)
Presenting Author:
Authors: Pavel M, Hörsch D, Hoffmanns P, Biran T, Houchard A,
Keywords: carcinoid syndrome, 5-HIAA, telotristat,